New hope to advanced breast cancer patients
GlaxoSmithKline (GSK) Bangladesh Limited announced recently an important milestone for advanced breast cancer patients in Bangladesh with the launch of the first oral ErbB1 (EGFR) and ErbB2 (HER2) dual inhibitor, Tykerb (lapatinib), says a press release.
Advanced breast cancer is the leading cause of cancer related deaths in women. Tykerb, through its novel mode of action has the potential to overcome the current limitations in the treatment of advanced breast cancer, GSK claims.
Experts expressed their optimism that with the introduction of Tykerb, women with advanced breast cancer will see a ray of hope in Bangladesh.
For all latest news, follow The Daily Star's Google News channel.
Comments